{
  "@context": "https://frontierpicks.com/schemas/dossier.v1.json",
  "ticker": "CRNX",
  "name": "Crinetics Pharmaceuticals, Inc.",
  "url": "https://frontierpicks.com/dossiers/CRNX/",
  "json_url": "https://frontierpicks.com/dossiers/CRNX.json",
  "status": "DORMANT",
  "current_conviction": "LOW",
  "graded_conviction": null,
  "archetype": {
    "code": "a5",
    "n": 5
  },
  "current_thesis": "Not a narrative any more: the Vertex $85.00/share cash takeout cleared HSR on 2026-08-12, the stockholder vote is 2026-08-28, and closing is guided to early September. At the 2026-08-14 close of $84.70 the gap to terms is $0.30 against roughly $42 of downside on a break — a three-week deal calendar, not a momentum leg.",
  "invalidation_trigger": "A daily close below $82 — a discount to fixed $85.00 cash terms far wider than a cleared deal three weeks from a guided early-September close justifies. Secondary: the 2026-08-28 special meeting failing to adopt the merger, or the Australian waiting period extending past 2026-08-27.",
  "catalyst_date": "2026-08-28",
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "m-and-a-special-situations",
    "rare-disease-gene-therapy",
    "precision-biotech-therapeutics"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "2026-07-06: Vertex to acquire CRNX for $85.00/share cash, ~$10B total; assets Palsonify (approved acromegaly) + atumelnant (late-stage CAH), Vertex sees $5B+ peak sales.",
    "Merger consideration is fixed all-cash $85.00/share — no stock component, so there is no exchange ratio or acquirer hedge to construct.",
    "Company withdrew its prior outlook on 2026-08-03 and will not issue updated guidance while the merger is pending.",
    "Record date for the 2026-08-28 special meeting was 2026-07-27; shares acquired after that date carry no vote.",
    "On closing, shares are expected to be delisted and deregistered — the security stops trading rather than repricing.",
    "Momentum screen fields (RSI 74, +130% 3-month, 0% from 52-week high) are residue of the 2026-07-07 announcement gap, not trend."
  ],
  "body_markdown": "## Current Thesis\n\nThe equity narrative terminated on 2026-07-06 when Vertex Pharmaceuticals agreed to acquire Crinetics for $85.00 a share in cash. What has changed since the last note is that the deal's regulatory leg is essentially finished: the 8-K filed 2026-08-14 discloses the HSR Act waiting period expired at 12:45 p.m. ET on 2026-08-12, with clearances also obtained in Austria, Germany and Australia as of 2026-08-13. The remaining gates are the Australian waiting period, scheduled to expire 2026-08-27 at 9:59 a.m. ET, and the stockholder vote at a virtual special meeting on 2026-08-28 at 9:00 a.m. PT. Closing is guided to early September 2026.\n\nAt the 2026-08-14 close of $84.70, the gap to fixed terms is $0.30. The screen fields around this name — RSI(14) 74.0, 0.0% from the 52-week high, +130.4% over three months — are arithmetic residue of one overnight gap, not evidence of trend. The narrative is dead. The narrative did not fail; it was bought, and the instrument converts to a fixed cash number in roughly three weeks.\n\n## Bull Case\n\n- Regulatory risk has been retired, not assumed away: HSR expiry timestamped 12:45 p.m. ET 2026-08-12; Austria, Germany and Australia cleared per the 2026-08-14 8-K. There was no second request.\n- Consideration is fixed all-cash at $85.00/share from a cash-generative strategic buyer, so there is no exchange ratio to hedge and no financing contingency to unwind. The board's recommendation was unanimous per the DEFM14A filed 2026-07-31.\n- The underlying business printed above consensus into the vote: Q2 revenue $25.118M versus a $14.840M estimate and EPS $(1.14) versus $(1.24) on 2026-08-03 — no operational deterioration that a buyer could point at.\n- The Street has converged on the deal price as terminal value: UBS moved to Neutral with the target raised to $85 on 2026-07-28, following HC Wainwright and Evercore ISI at $85 (2026-07-08) and Baird's Outperform at $85.\n- Residual upside exists only via a competing bid above $85. Nothing dated supports one; it is the only mechanism left that changes the terminal number.\n\n## Bear Case\n\n- The payoff is $0.30 up to terms against roughly $42 down to the pre-announcement reference near $42 on a break. Three weeks of calendar risk buys a rounding error of upside.\n- Vote arithmetic is a real condition, not a formality: adoption requires a majority of the 106,095,205 shares outstanding as of the 2026-07-27 record date, per the DEFM14A. Turnout failure and adoption failure look identical to the tape.\n- The company withdrew its prior outlook and said on 2026-08-03 it will not provide updated guidance. There is no forward company disclosure to reprice against if the deal slips.\n- Retail-facing coverage clustered at the top of the move — a \"$1,000 invested 5 years ago\" retrospective 2026-07-08, CNBC \"Final Trades\" name-checking Vertex 2026-07-09, a \"7 Small Caps on Fire\" roundup 2026-07-21, and a \"Health Care Stocks That May Implode In August\" list 2026-08-12. That mix arrives after the event, not before it.\n- The Australian clearance is still inside a waiting period through 2026-08-27 at 9:59 a.m. ET. It is the last unexpired regulatory clock and it sits one day before the vote.\n\n## Setup & Price Structure\n\nThere is no momentum structure to read. Price gapped from roughly $42 to $83.53 on 2026-07-07 (+98.7% that session) and has since ground toward terms, closing 2026-08-14 at $84.70. Moving averages are still climbing out of the pre-deal range and carry no information about the next three weeks; the $85.00 cash figure caps the top and the unaffected level near $42 sets the downside reference. Realized volatility should stay compressed while every condition is on track, with the band tightening toward $85 as the vote approaches.\n\nCrowding observables, stated plainly: distance above a rising 20-EMA is an artifact of the gap rather than accumulation; the earnings binary is already behind (Q2 printed 2026-08-03); no insider transactions or issuance into strength appear in the recent filing record; and coverage density peaked in the week after announcement rather than now. One standing data-quality caveat carried from earlier work: feed market-cap fields printed a stale ~$4.4B alongside the $83.53 quote on 2026-07-07 — a lagged pre-deal figure. Anchor on announced terms. Deal-value characterizations differ by source: approximately $10B at announcement, with trade coverage (InsideArbitrage, July 2026) citing ~$8.8B net of cash.\n\n## Catalyst Calendar (next 30 days)\n\n- 2026-08-27, 9:59 a.m. ET — Australian antitrust waiting period expiry (per 8-K filed 2026-08-14). Last unexpired regulatory clock.\n- 2026-08-28, 9:00 a.m. PT — virtual special meeting of Crinetics stockholders to adopt the merger agreement; majority of 106,095,205 outstanding shares required.\n- ~2026-08-28 to 2026-08-31 (est.) — 8-K reporting the vote result, typically filed within four business days of the meeting.\n- Early September 2026 (company-guided, no fixed date) — expected closing, followed by delisting and deregistration.\n\n## What Would Change Our Mind\n\nThe structural break here is a condition failing, not a chart breaking. Three things would do it: the 2026-08-28 special meeting adjourning or failing to secure a majority of the 106,095,205 outstanding shares; the Australian waiting period being extended past 2026-08-27 rather than lapsing; or the guided early-September closing window passing with no closing 8-K and no explanatory filing. Any of those converts a $0.30 spread into a repricing toward the ~$42 unaffected level.\n\nExpressed as a gradeable market condition: a daily close below $82 would mark a discount to fixed $85.00 cash terms far wider than a cleared, three-weeks-to-close deal warrants, and would be the market pricing break risk rather than time value. A close above $85 would carry the opposite information — a competing bid or the expectation of one — and is the only path to a terminal number higher than $85.00.\n\n## Correlation Notes\n\n- Correlation to biotech beta (XBI) and to rates is broken while the deal is intact; the name trades against the deal calendar, and Vertex's own tape is not a driver of CRNX's price.\n- The relevant peer set is other cleared, all-cash pharma takeouts pending a shareholder vote, where spreads compress into the meeting date and gap only on a condition failure.\n- A sector-wide antitrust shock is the main channel that could reprice this alongside other pending healthcare deals, but the US waiting period here has already expired.\n- Screen-driven momentum and 52-week-high scans will keep surfacing this name into the vote purely on the July gap; that flow carries no information about the deal's conditions.",
  "first_seen": "2026-07-10",
  "last_analyzed": "2026-08-16T15:01:39+00:00",
  "last_synthesized": "2026-08-16",
  "last_update_source": "watchlist_research",
  "license": "Content © FrontierPicks. Cite the canonical URL."
}